Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sherry Grooms

Nurse Practitioner Beavercreek, OH Nurse Practitioner

NPI 1528043106 CMS profile 11182444

3572 Dayton Xenia Rd, Suite 105, Beavercreek, OH 45432

Open in the dashboard

General payments

$11,574

647 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherry Grooms of Beavercreek, OH is reported in the CMS Open Payments database as having received $11,574 across 647 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,355 182
2024 General $3,223 175
2023 General $2,481 126
2022 General $1,563 92
2021 General $953 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherry Grooms
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sherry Grooms were reported at $3,355. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sherry Grooms Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $953 $135 $40–$426 $132
2022 $1,563 $152 $48–$470 $149
2023 $2,481 $166 $54–$529 $160
2024 $3,223 $173 $55–$556 $164
2025 $3,355 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,039 181 payments
  2. Regeneron Healthcare Solutions, Inc. $1,421 61 payments
  3. Janssen Biotech, Inc. $1,083 52 payments
  4. Genzyme Corporation $796 33 payments
  5. Pfizer Inc. $721 64 payments
  6. Novartis Pharmaceuticals Corporation $720 33 payments
  7. Lilly USA, LLC $686 31 payments
  8. Amgen Inc. $584 27 payments
  9. E.R. Squibb & Sons, L.L.C. $579 32 payments
  10. UCB, Inc. $542 20 payments
  11. Other $2,400 113 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,905 635 payments
  2. Education $669 12 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $957 42 payments
  2. DUPIXENT Immunology $886 41 payments
  3. SKYRIZI $885 89 payments
  4. DUPIXENT Inflammation And Immunology $723 34 payments
  5. RINVOQ $670 47 payments
  6. VTAMA $593 25 payments
  7. Otezla $584 27 payments
  8. SOTYKTU $579 32 payments
  9. TALTZ $517 28 payments
  10. DUPIXENT Immunology And Inflammation $505 15 payments
  11. Other $6,372 447 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,693

Median for Nurse Practitioner: 389

Drug cost

$1,182,084

Median for Nurse Practitioner: $21,885

Branded share of claims

14.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 58 $582,845
Otezla Apremilast Brand 30 $148,017
Dupixent Pen Dupilumab Brand 40 $146,507
Rinvoq Upadacitinib Brand 23 $144,093
Cosentyx Unoready Pen Secukinumab Brand 12 $111,699
Clobetasol Propionate Generic 144 $7,461
Pimecrolimus Generic 14 $6,564
Fluorouracil Generic 68 $6,408
Metronidazole Generic 42 $2,800
Doxycycline Monohydrate Generic 68 $2,505

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$141,843

Of which drugs: $186

Medicare patients

442

Average age 76

Services billed

3,975

282 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 50%
Diabetes 29%
Ischemic heart disease 26%
Chronic kidney disease 24%
Depression 22%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 47 277 $186

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $234
  • GENZYME CORPORATION $117
$351 40 —
VTAMA
  • Dermavant Sciences, Inc. $336
$336 — —
SKYRIZI
  • AbbVie, Inc. $247
$247 — —
RINVOQ
  • AbbVie, Inc. $227
$227 23 —
TREMFYA
  • Janssen Biotech, Inc. $193
$193 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

647 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record